Vistagen Therapeutics (VTGN): Growth-Adjusted Market Cap to Net Income

Symbol and logo of brand VistaGen Therapeutics Inc (VTGN)

Vistagen Therapeutics (VTGN) is developing fast-acting nasal anxiety treatments with a low incidence of side effects. The PEG fair value filter confirms the asset's potential, with the current metric standing at 0.00. Growth is supported by bioinformatic IT systems that automate drug discovery. Market confidence is bolstered by the leadership of Sean Singh, who has successfully attracted significant institutional capital for the final stages of clinical trials.

VTGN - vistagen.com PEG Multiple over the range 07/04/2022 - 11/17/2026

Analytical breakdowns for Vistagen Therapeutics (VTGN)

Fundamental company analysis:vistagen.com (VTGN)
Manufactured product of VistaGen Therapeutics Inc

When constructing a long-term portfolio, fundamental screening requires correlating market value with earnings dynamics. This indicator divides the P/E ratio by the EPS growth rate to determine whether the valuation is fair relative to operational expansion. For Vistagen Therapeutics (VTGN), growth potential is embedded in the market launch of safe nasal sprays without side effects. Values below one signal that the asset is undervalued. By analyzing the P/E-to-growth chart, an investor identifies entry points for "moonshot" stocks.

Who Vistagen Therapeutics competes with

Growth-Adjusted Market Cap to Net Income Biogen Idec|Neurocrine Corp - Price/Earnings to Growth Multiple|regencellbioscience.com (RGC) - Price to Earnings Adjusted for Growth Rate|AXSM - Price/Earnings to Growth Ratio|ACAD (ACADIA Pharmaceuticals Inc.) - Growth-Adjusted P/E Ratio|Xenon Pharmaceuticals (XENE) - Price/Earnings to Growth Ratio|Growth-Adjusted P/E Ratio VKTX|Price/Earnings to Growth Ratio Supernus|Price to Earnings Adjusted for Growth Rate catalystpharma.com CPRX|Price/Earnings to Growth Multiple DNLI (Denali Therapeutics Inc.)|HRMY - Price to Earnings Adjusted for Growth Rate|Price/Earnings to Growth Ratio Biohaven Ltd. BHVN|AMLX (Amylyx) - Market Cap to Earnings and Growth Ratio|Trevi Therapeutics Inc - PEG Multiple|Growth-Adjusted Payback Ratio PRAX (Praxis Precision Medicines)|AVXL: PEG Multiple|CBLL - Growth-Adjusted Market Cap to Net Income|Price/Earnings to Growth Ratio prothena.com|Price/Earnings to Growth Multiple Alector (ALEC)|Price/Earnings to Growth Multiple ANNX (annexonbio.com)|OMER - Price to Earnings Adjusted for Growth Rate|PEG Multiple NGNE (Neurogene Inc)|PEG Multiple AC Immune S.A. ACIU|VYGR - Price/Earnings to Growth Ratio|Market Cap to Earnings and Growth Ratio NMRA|SCLX (Scilex Holding Company) - Price/Earnings to Growth Multiple|TVGN (Tevogen Bio Holdings) - Price/Earnings to Growth Ratio|ACOG (Alpha Cognition Corp) - PEG Multiple|Cognition Therapeutics, Inc. - Market Cap to Earnings and Growth Ratio|PEG Multiple IKT|SAVA (Cassava) - Growth-Adjusted Payback Ratio|Assertio Holdings, Inc. - Price/Earnings to Growth Multiple|Growth-Adjusted Payback Ratio COYA|Ovid Therapeutics Inc - PEG Multiple|Acumen Pharmaceuticals, Inc. (ABOS) - Price/Earnings to Growth Multiple|CRVO (CervoMed, Inc.) - Price/Earnings to Growth Multiple|Price/Earnings to Growth Multiple Alterity Therapeutics Ltd|Price/Earnings to Growth Ratio Clene Inc.|PepGen Inc. - Market Cap to Earnings and Growth Ratio|Price/Earnings to Growth Multiple JUNS (Jupiter Neurosciences Inc)|Price/Earnings to Growth Ratio RLMD (Relmada Therapeutics Inc)|Annovis Bio Inc - Price/Earnings to Growth Multiple|Growth-Adjusted Market Cap to Net Income Grace Tx (GRCE)|fireflyneuro.com - PEG Multiple|Klotho Neurosciences (KLTO) - Price/Earnings to Growth Multiple|NeuroSense Therapeutics, Ltd. (NRSN) - Price/Earnings to Growth Ratio|Market Cap to Earnings and Growth Ratio RVPH (Reviva Pharmaceuticals Holdings, Inc.)|MTVA (MetaVia) - PEG Multiple|NRXS: Growth-Adjusted Payback Ratio|PEG Multiple HSDT|PEG Multiple Passage Bio Inc. (PASG)|Price/Earnings to Growth Ratio bionomics.com.au NEUP|PEG Multiple Minerva Neurosciences Inc NERV|ATHA: Price/Earnings to Growth Multiple|ADXN (Addex Therapeutics, Ltd.) - Growth-Adjusted P/E Ratio|Alzamend Neuro Inc. (ALZN) - Price/Earnings to Growth Ratio|Cyclerion - Growth-Adjusted Payback Ratio|Price/Earnings to Growth Ratio protagenic.com|Pasithea Therapeutics - Market Cap to Earnings and Growth Ratio|Price/Earnings to Growth Multiple CRGT (Cortigent, Inc.)|Avenue Therapeutics - Growth-Adjusted P/E Ratio|Price/Earnings to Growth Ratio Brainstorm Cell BCLI|PEG Multiple caratherapeutics.com CARA|Chromocell Therapeutics Corp. - PEG Multiple|eliemtx.com - Company Value to Earnings Growth Ratio|Intra-Cellular Therapies (ITCI) - Price/Earnings to Growth Ratio|LBPH (Longboard) - Price/Earnings to Growth Ratio|MRNS (marinuspharma.com) - PEG Multiple|Price to Earnings Adjusted for Growth Rate NKGen Biotech NKGN|Price/Earnings to Growth Ratio NeuroBo Pharma (NRBO)|Company Value to Earnings Growth Ratio SAGE|Synaptogenix, Inc. - Price/Earnings to Growth Multiple|TRVN: Growth-Adjusted P/E Ratio|VIGL - Price/Earnings to Growth Ratio|Growth-Adjusted Payback Ratio WENA (Anew Medical, Inc.)|CERE: PEG Multiple